<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04882904</url>
  </required_header>
  <id_info>
    <org_study_id>ActiLiège. ActiSLA part.</org_study_id>
    <nct_id>NCT04882904</nct_id>
  </id_info>
  <brief_title>Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.</brief_title>
  <official_title>Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Stéphanie Delstanche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sysnav</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Liege</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Régional de la Citadelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ActiSEP is a monocentric academic study. Patients with amyotrophic lateral sclerosis may be&#xD;
      included on a voluntary basis. The investigators plan to include a group of approximately 45&#xD;
      patients with ALS.&#xD;
&#xD;
      The investigators have planned to assess patient every three months for a year. On each&#xD;
      visit, participants will undergo a clinical examination with MRC sum score and Ashworth&#xD;
      scores.&#xD;
&#xD;
      They will perform few tests ( 6-minutes walk test (6MWT), dynamometric measure,&#xD;
      electromyography, Edinburgh Cognitive and Behavioural ALS Screen ) and will answer to some&#xD;
      questionaires (dysphagia handicap scale, ALS-SFR-r).&#xD;
&#xD;
      After each visit, participants will wear Actimyo for one month daily.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients undergo clinical evaluation and wear Actimyo device in daily living to evaluate their evolution.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>95th centile of stride velocity</measure>
    <time_frame>1 year</time_frame>
    <description>95th centile of stride velocity obtained with a magneto-inertial sensor (Actimyo°) in real-life (meter per second).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>50th centile of stride velocity</measure>
    <time_frame>1 year</time_frame>
    <description>50th centile of stride velocity obtained with a magneto-inertial sensor (Actimyo°) in real-life (meter per second).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>95th centile of stride length</measure>
    <time_frame>1 year</time_frame>
    <description>95th centile of stride length obtained with a magneto-inertial sensor (Actimyo°) in real-life (meter).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>50th centile of stride length</measure>
    <time_frame>1 year</time_frame>
    <description>50th centile of stride length obtained with a magneto-inertial sensor (Actimyo°) in real-life (meter).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Upper limb function evolution in patient with ALS</measure>
    <time_frame>1 year</time_frame>
    <description>Upper limb function assessed with a magneto-inertial sensor (Actimyo°) in real-life.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Patient with ALS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with amyotrophic lateral sclerosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Actimyo°</intervention_name>
    <description>Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.</description>
    <arm_group_label>Patient with ALS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically defined or probable diagnosis of ALS according to El Escorial criteria&#xD;
             revised with Awaji's electro-diagnostic algorithm.&#xD;
&#xD;
          -  Over 18 years old.&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  If patient on Riluzole, the dosage should be stable for 1 month and continued&#xD;
             throughout the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with excessive cognitive disorders, limiting the understanding of task or&#xD;
             with apparent communication difficulties hindering data collection.&#xD;
&#xD;
          -  Any other previous or present pathology having an impact on motor function.&#xD;
&#xD;
          -  Recent surgery or trauma (less than 6 months) in the upper or lower limbs.&#xD;
&#xD;
          -  Prior neurological, endocrine, infectious, allergic, or chronic or acute inflammatory&#xD;
             pathology in the three weeks preceding inclusion.&#xD;
&#xD;
          -  Patients participating in an interventional clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaux Poleur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR Citadelle-CHU liège</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Buscemi</last_name>
    <phone>43215584</phone>
    <phone_ext>0032</phone_ext>
    <email>Laura.Buscemi@chrcitadelle.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Buscemi</last_name>
      <phone>43215584</phone>
      <phone_ext>0032</phone_ext>
      <email>Laura.Buscemi@chrcitadelle.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Régional de la Citadelle</investigator_affiliation>
    <investigator_full_name>Dr. Stéphanie Delstanche</investigator_full_name>
    <investigator_title>Coordinator of reference center for neuromuscular diseases</investigator_title>
  </responsible_party>
  <keyword>Actimyo</keyword>
  <keyword>Accelerometry</keyword>
  <keyword>Daily living</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

